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Abstract
Background: Telomeres play a key role in the maintenance of chromosome integrity and stability, and telomere shortening
is involved in initiation and progression of malignancies. A series of epidemiological studies have examined the association
between shortened telomeres and risk of cancers, but the findings remain conflicting.
Methods: A dataset composed of 11,255 cases and 13,101 controls from 21 publications was included in a meta-analysis to
evaluate the association between overall cancer risk or cancer-specific risk and the relative telomere length. Heterogeneity
among studies and their publication bias were further assessed by the x
2-based Q statistic test and Egger’s test,
respectively.
Results: The results showed that shorter telomeres were significantly associated with cancer risk (OR=1.35, 95% CI=1.14–
1.60), compared with longer telomeres. In the stratified analysis by tumor type, the association remained significant in
subgroups of bladder cancer (OR=1.84, 95% CI=1.38–2.44), lung cancer (OR=2.39, 95% CI=1.18–4.88), smoking-related
cancers (OR=2.25, 95% CI=1.83–2.78), cancers in the digestive system (OR=1.69, 95% CI=1.53–1.87) and the urogenital
system (OR=1.73, 95% CI=1.12–2.67). Furthermore, the results also indicated that the association between the relative
telomere length and overall cancer risk was statistically significant in studies of Caucasian subjects, Asian subjects,
retrospective designs, hospital-based controls and smaller sample sizes. Funnel plot and Egger’s test suggested that there
was no publication bias in the current meta-analysis (P=0.532).
Conclusions: The results of this meta-analysis suggest that the presence of shortened telomeres may be a marker for
susceptibility to human cancer, but single larger, well-design prospective studies are warranted to confirm these
findings.
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Introduction
Telomeres, a series of tandem repeats of TTAGGG nucleotides,
cap the ends of chromosomes in all eukaryotic cells [1] and
maintain genomic stability by prohibiting fatal events, such as
nucleolytic degradation, chromosomal end-to-end fusion and
irregular recombination [2]. Human telomeres are approximately
10–15 kb in somatic cells and progressively shortened by ,30 to
200 bp after each cycle of mitotic division, due to incomplete
replication of linear DNA molecules and the absence of a
mechanism for elongation of telomeres [3]. When the telomeres
reach a critical length, Rb and p53 signaling pathways are
triggered to initiate either cell senescence or apoptosis [4]. Thus,
telomere length has been suggested as a ‘‘cellular mitotic clock’’
that defines the number of cell divisions and cellular life span [1,5].
Several studies have documented correlations between short-
ened telomeres and multiple human diseases associated with age,
such as Alzheimer’s disease [6], myocardial infarction [7], vascular
dementia [8], liver cirrhosis [9], atherosclerosis [10], ulcerative
colitis [11] and premature aging syndromes [12]. Additionally,
telomere shortening is involved in initiation and progression of
malignancies in mouse models and functional studies [13,14]. For
example, short telomeres cause an increased risk of developing
epithelial cancers by the formation of complex non-reciprocal
translocations [15,16], and telomeres in tumor cells and their
precursor lesions are significantly shorter than that in surrounding
non-tumor cells [17,18].
Although evidence from functional studies and animal models
support the hypothesis that telomere shortening contributes
to tumor development, results from population studies remain
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e20466conflicting rather than conclusive [19–44]. For instance, several
case-control studies have investigated the association between
telomere length in peripheral blood lymphocytes and breast cancer
risk [21,25,29,31,35,36,38]; some showed that shorter telomeres
were associated with increased risk of breast cancer [31,38], while
others indicated converse or insignificant associations [21,25,29,
35,36]. These findings suggest that any of these single studies may
have been underpowered to detect the association between telo-
mere length and cancer risk because of their limited sample sizes.
Furthermore, the underlying heterogeneity among different studies
can be explored in a meta-analysis. Thus, we conducted a syste-
matic meta-analysis on 21 relevant publications with 11,255 cases
and 13,101 controls to estimate the overall cancer risk or cancer-
specific risk associated with telomere length and to evaluate
potential between-study heterogeneity of these published studies.
Materials and Methods
Search strategy and selection criteria
We used two electronic databases (MEDLINE and EMBASE)
to identify all case-control studies published to date on an
association between telomere length and cancer risk (last search
update in November, 2010, using the search terms ‘‘telomere
length’’, ‘‘cancer’’ or ‘‘carcinoma’’, and ‘‘risk’’). Additional studies
were identified by a hands-on search of references of original
studies or reviews on this topic. Authors were also contacted
directly, if crucial data were not reported in original papers.
Studies included in the current meta-analysis had to meet the
following criteria: written in English; case-control design; sufficient
information needed to estimate odds ratios (ORs) and their 95%
confidence intervals (CIs); independent from other studies to avoid
double weighting in the estimates derived from the same study. In
addition, investigations in subjects with cancer-prone disposition
were excluded from the analysis.
Data extraction
Two authors (HM and ZZ) independently extracted data and
reached a consensus on all of the items. The following information
was extracted from each report: the first author, year of
publication, country of origin, ethnicity, cancer type, the number
of cases and controls grouped by median or quartiles of relative
telomere length (T/S ratio), study type, control source (population-
based and hospital-based), DNA source, and measurement
methods for telomere length. For studies including subjects of
different racial descent, data were extracted separately for each
ethnic group (categorized as Caucasian, Asian or others). When a
study did not state what ethnic groups were included or if it
was impossible to separate participants according to the data
presented, the sample was termed as ‘other populations’. Further-
more, references involved in different ethnic groups, different types
of cancer and different institutions were divided into multiple
study samples for subgroup analyses.
Quantitative data synthesis
The number of cases and controls grouped by the median of the
relative telomere length (T/S ratio) was collected from each study
to evaluate the risk of cancers (ORs and 95% CI). For each study,
a median value of the relative telomere length (T/S ratio) in
controls was considered as a cut-point dividing all subjects into two
groups: the longer telomere group and the shorter telomere group.
The association between the relative telomere length (T/S ratio)
and cancer risk was examined by ORs and 95% CIs with the
group of longer telomeres as the reference. The stratification
analyses were also conducted by cancer type (if one cancer type
was investigated in less than three studies, it would be merged into
the ‘other cancers’ group), study type (retrospective and prospec-
tive), ethnicity (Caucasian, Asian or others), control source
(hospital-based and population-based) and sample size (,500,
500–1000 and .1000). Smoking-related cancers were defined as
those of the lung, bladder, head and neck, kidney and pancreas;
and cancers of the digestive system included those of the stomach,
esophagus and colon. Additionally, cancers arising from the
bladder, kidney and prostate sites were considered cancers of the
urogenital system.
The x
2-based Q test was performed to assess between-study
heterogeneity and considered significant if P,0.05 [45]. Hetero-
geneity was also quantified with the I
2 statistic, a value that
indicates what proportion of the total variation across studies is
beyond chance, where 0% indicates no observed heterogeneity
and larger values show increasing heterogeneity [46]. The fixed-
effects model and the random-effects model, based on the Mantel-
Haenszel method [47] and the DerSimonian and Laird method
[48], respectively, were used to combine values from different
studies. When P value of the heterogeneity test was $0.05, the
fixed-effects model was used, which assumes the same homoge-
neity of effect size across all studies; otherwise, the random-effects
model was more appropriate, which tends to provide wider
confidence intervals, when the results of the constituent studies
differ among themselves. To evaluate the effect of individual
studies on the overall risk of cancers, sensitivity analyses were
performed by excluding each study individually and recalculating
the ORs and 95% CI. Furthermore, a sensitivity analysis was also
performed each by excluding three studies whose matching
information was unavailable [21,25,35], two studies whose DNA
were not from blood [20,34], and three studies that did not use
quantitative PCR to test relative telomere length(T/S ratio)
[19,22,36]. The inverted funnel plots and Egger’s test (linear
regression analysis) were used to investigate publication bias [49].
All analysis was conducted by using Review Manage (v.5.0) and
Stata 10.0. All P values were two-sided.
Figure 1. Flow chart for the process of selecting the final 21
publications.
doi:10.1371/journal.pone.0020466.g001
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Characteristics of Studies
As shown in Fig. 1, a total of 146 published records were
retrieved by using the key words mentioned earlier in the
Methods, of which 26 examined the association between telomere
length and cancer risk. Among those 26 publications, five were
excluded either because they did not provide available data to
extract the ORs and 95% CI [40,41,43,44] or the subjects were of
cancer-prone predisposition [42]. The remaining 21 publications
of case-control studies contained 29 studies (Wu’s and Pooley’s
studies had datasets of four different cancers and McGrath’s
and Zheng’s studies had datasets of two different sources)
[19,23,36,38]. The essential information, including first author,
year of publication, country, ethnicity, cancer type, numbers of
cases and controls, study type, control source and DNA source for
all studies are listed in Table 1. Our meta-analysis included nine
breast cancer studies [21,29,31,35,36,38], four bladder studies
[19,20,23], three lung cancer studies [19,24,34], two renal cancer
studies [19,22], two gastric cancers [27,30], two colorectal cancers
[38] and seven studies of other cancers [19,26,28,32,33,37]
(Table 1). Because some controls in one publication [19] were
Table 1. Characteristics of studies included in the meta-analysis.
Author Year Country Ethnicity Cancer type
cases
/controls Study type Control source DNA source
Measurement
methods
Wu [19] 2003 USA Caucasian Head and neck
cancer
92/92 Retrospective Hospital-based Lymphocytes Southern Blot
Analysis
Wu [19]
a 2003 USA Caucasian Bladder cancer 135/135 Retrospective Hospital-based Lymphocytes Q-FISHLSC
Wu [19]
a 2003 USA Caucasian Lung cancer 54/54 Retrospective Hospital-based Lymphocytes Q-FISHLSC
Wu [19]
a 2003 USA Caucasian Renal cell
carcinoma
32/32 Retrospective Hospital-based Lymphocytes Q-FISHLSC
Broberg [20] 2005 Sweden Caucasian Bladder cancer 63/93 Retrospective Population-based Buccal cells Quantitative PCR
Shen [21] 2007 USA Mixed Breast cancer 283/347 Retrospective Family-based White blood cells Quantitative PCR
Shao [22] 2007 USA Mixed Renal Cancer 65/65 Retrospective Hospital-based Lymphocytes Q-FISHLSC
McGrath [23] 2007 USA Not defined Bladder cancer
(NHS)
61/67 Prospective Population-based Buffy coat Quantitative PCR
McGrath [23] 2007 USA Not defined Bladder cancer
(HPFS)
123/125 Prospective Population-based Buffy coat Quantitative PCR
Jang [24] 2008 Korea Asian Lung cancer 243/243 Retrospective Hospital-based Whole blood Quantitative PCR
Svenson [25] 2008 Sweden European Breast cancer 265/446 Retrospective Population-based Buffy coat,
granulocyte
Quantitative PCR
Mirabello [26] 2009 USA Caucasian Prostate cancer 612/1049 Prospective Population-based Buffy coat Quantitative PCR
Liu [27] 2009 China Asian Gastric cancer 396/378 Retrospective Hospital-based Whole blood Quantitative PCR
Xing [28] 2009 USA Caucasian Esophageal cancer 94/92 Retrospective Hospital-based Whole blood Quantitative PCR
De Vivo [29] 2009 USA Caucasian Breast cancer 896/917 Prospective Population-based Lymphocytes Quantitative PCR
Hou [30] 2009 Poland Caucasian Gastric cancer 300/416 Retrospective Population-based Lymphocytes Quantitative PCR
Shen [31] 2009 USA Mixed Breast cancer 1026/1070 Retrospective Population-based Mononuclear cells Quantitative PCR
Lan [32] 2009 Finland Caucasian Non-Hodgkin
Lymphoma
107/107 Prospective Population-based Whole blood Quantitative PCR
Han [33] 2009 USA Caucasian Skin cancer 740/801 Prospective Population-based Buffy coat Quantitative PCR
Hosgood [34] 2009 China Asian Lung cancer 109/97 Retrospective Population-based Sputum Quantitative PCR
Gramatges [35] 2010 USA Mixed Breast cancer 102/50 Retrospective Population-based Whole blood Quantitative PCR
Zheng [36] 2010 USA Mixed Breast cancer
(RPC1)
152/176 Retrospective Hospital-based Buffy coat Quantitative PCR
Zheng [36] 2010 USA Mixed Breast cancer
(LCCC)
140/159 Retrospective Hospital-based Buffy coat Q-FISHLSC
Mirabello [37] 2010 Poland Caucasian Ovarian cancer 98/100 Retrospective Population-based Buffy coat Quantitative PCR
Pooley [38] 2010 UK Caucasian Breast cancer
(SEARCH)
2243/2181 Retrospective Population-based Blood Quantitative PCR
Pooley [38] 2010 UK Caucasian Breast cancer
(EPIC)
199/420 Prospective Population-based Blood Quantitative PCR
Pooley [38] 2010 UK Caucasian Colorectal cancer
(SEARCH)
2161/2249 Retrospective Population-based Blood Quantitative PCR
Pooley [38] 2010 UK Caucasian Colorectal cancer
(EPIC)
185/406 Prospective Population-based Blood Quantitative PCR
Prescott [39] 2010 USA Caucasian Endometrial cancer 279/791 Prospective Population-based Blood Quantitative PCR
aSome controls were shared. PCR, polymerase chain reaction; Q-FISHLSC, quantitative fluorescence in situ hybridization-based approaches.
doi:10.1371/journal.pone.0020466.t001
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neck cancer, bladder cancer, lung cancer and renal cell carcinoma)
in the analysis stratified by tumor type but defined as one study in
the overall analysis and stratification analysis by ethnicity, study
type, control source and sample size. Overall, 15 studies used
Caucasians, three used Asians, and eight used other ethnic groups;
in addition, nine studies were prospective and seventeen were
retrospective; 18 studies were population-based, seven were
hospital-based, and one was family-based [21]. Most of studies
provided matching information by age and/or other variables
except for three studies [21,25,35]. The quantitative PCR was the
most frequently used method to measure the relative telomere
length (T/S ratio), while three studies used other assays including
southern blot telomere restriction fragment (TRF) and quantitative
fluorescence in situ hybridization-based approaches (Q-FISH)
[19,22,36]. Additionally, the blood was the most common source
of DNA, although other sources were also applied, such as buccal
cells and sputum [20,34].
Meta-analysis results
We obtained the telomere genotyping data from 21 publications
consisting of 11,255 cases and 13,101 controls. When all eligible
studies were pooled into the meta-analysis, we found that shorter
telomeres were significantly associated with the overall cancer risk
(OR=1.35, 95% CI=1.14–1.60, P,0.001 for heterogeneity test,
I
2=88%; Fig. 2). In the stratified analysis by tumor type
(Table 2), the comparisons showed that individuals with shorter
telomeres had an increased risk of bladder cancer (OR=1.84,
95% CI=1.38–2.44, P=0.88 for heterogeneity test, I
2=0%) and
lung cancer (OR=2.39, 95% CI=1.18–4.88, P=0.009 for
heterogeneity test, I
2=79%); but not breast cancer (OR=1.04,
95% CI=0.77–1.40, P,0.001 for heterogeneity test, I
2=92%).
We also found the association between the relative telomere length
and overall cancer risk was statistically significant in studies of
Caucasian subjects (OR=1.30, 95% CI=1.06–1.61, P,0.001 for
heterogeneity test, I
2=90%), Asian subjects (OR=2.08, 95%
CI=1.31–3.30, P,0.001 for heterogeneity test, I
2=75%),
retrospective design (OR=1.44, 95% CI=1.13–1.84, P,0.001
for heterogeneity test, I
2=86%), hospital-based controls
(OR=2.01, 95% CI=1.54–2.62, P=0.01 for heterogeneity test,
I
2=62%), and sample sizes less than 500 (OR=1.51, 95%
CI=1.06–2.16, P,0.001 for heterogeneity test, I
2=83%).
Furthermore, when cancers were grouped into site-specific types
(Fig. 3), the results showed that the association remained
significant for smoking-related cancers (OR=2.25, 95%
CI=1.83–2.78, P=0.07 for heterogeneity test, I
2=54%), cancers
in the digestive system (OR=1.69, 95% CI=1.53–1.87, P=0.14
for heterogeneity test, I
2=42%) and in the urogenital system
(OR=1.73, 95% CI=1.12–2.67, P,0.001 for heterogeneity test,
I
2=78%).
Figure 2. Odds ratios (ORs) and 95% confidence intervals (CIs) for overall cancer risk associated with relative telomere length
(shorter vs. longer, grouped by the median of telomere length ratio).
a Some controls were shared in the study by Wu et al (2003) that
included a total of 313 cases and 256 controls.
doi:10.1371/journal.pone.0020466.g002
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Substantial heterogeneity was observed among all studies for the
relative telomere length and cancer risk (x
2=215.43, P,0.001,
Fig. 2). Therefore, we evaluated the source of heterogeneity by
tumortype,ethnicity,controlsource,studytypeandsamplesize,and
we found that tumor type and control source did contribute to
substantial heterogeneity (x
2=9.33, P=0.025 for tumor type and
x
2=9.88, P=0.002 for control source, respectively) but not from
ethnicity (x
2=3.90, P=0.143), study type (x
2=0.91,P=0.340) and
sample size (x
2=1.21, P=0.547). The leave-one-out sensitivity
analysis indicated that no single study changed the pooled ORs
qualitatively (data not shown). Furthermore, the sensitivity analysis
without three studies whose matching information was unavailable
[21,25,35], two studies whose DNA were not from blood [20,34], or
threestudieswithoutuseofquantitativePCRtotestrelativetelomere
length (T/S ratio) [19,22,36] did not alter the results of the meta-
analysis (OR=1.48, 95% CI=1.26–1.74, P,0.001 for heterogene-
ity test, I
2=87%; OR=1.34, 95% CI=1.12–1.59, P,0.001 for
heterogeneity test, I
2=89%; and OR=1.30, 95% CI=1.08–1.55,
P,0.001 for heterogeneity test, I
2=89%; respectively).
Publication bias
As shown in Fig. 4, the shapes of the funnel plots seemed
symmetrical, and Egger’s test suggested that there was no pub-
lication bias in the current meta-analysis (P=0.532). These
indicated that bias from publications might not have a significant
influence on the results of our meta-analysis on the association
between telomere length and cancer risk.
Discussion
In this meta-analysis of 11,255 cancer cases and 13,101 controls
from 21 independent publications, we found that shorter telomeres
were significantly associated with risk of cancer, especially cancers
of the bladder and lung, smoking-related, the digestive system and
the urogenital system. Furthermore, the stratification analysis also
showed that the association was more prominent in studies of
Caucasian subjects, Asian subjects, retrospective design, hospital-
based controls, and smaller sample sizes.
Studies have showed that telomeres are critical for maintaining
genomic integrity and that telomere dysfunction or shortening is
an early, common genetic alteration acquired in the multistep
process of malignant transformation [12,50]. In addition, telomere
dysfunction has been found to be associated with decreased DNA
repair capacity and complex cytogenetic abnormalities [51]. Both
of animal studies and clinical observations have shown that shorter
telomeres were associated with increased risk of cancers, such as
epithelial cancers [52,53,54]. However, telomere shortening might
play conflicting roles in cancer development. For example, the
progressive loss of telomeric repeats with each cell division can
induce replicative senescence and limit the proliferative potential
of a cell, thus functioning as a tumor suppressor [12,55]. But, once
telomeres reach a critical length, it will result in chromosome
Table 2. Associations between relative telomere length and cancer risk stratified by selected factors.
Variables No of studies
a Sample Shorter vs. longer P for Heterogeneity
Case/control OR(95%CI)
b OR(95%CI)
c
All 26 11,255/13,101 1.35 (1.14–1.60) 1.37 (1.30–1.44) ,0.00001
Tumor type
Breast cancer 9 5,306/5,766 1.04 (0.77–1.40) 1.29 (1.20–1.40) ,0.00001
Bladder cancer 4 382/420 1.83 (1.38–2.44) 1.84 (1.38–2.44) 0.88
Lung cancer 3 406/394 2.39 (1.18–4.88) 2.44 (1.82–3.27) 0.009
Other 13 5,161/6,578 1.47 (1.15–1.87) 1.37 (1.27–1.47) ,0.00001
Ethnicity
Caucasian 15 8,555/10,324 1.30 (1.06–1.61) 1.38 (1.30–1.46) ,0.00001
Asian 3 748/718 2.08 (1.31–3.30) 2.20 (1.78–2.72) ,0.00001
Other 8 1,952/2,059 1.21 (0.87–1.70) 1.11 (0.98–1.26) ,0.00001
Study type
Prospective 9 7,222/8,287 1.21 (0.93–1.57) 1.39 (1.30–1.48) ,0.00001
Retrospective 17 4,033/4,814 1.44 (1.13–1.84) 1.33 (1.22–1.45) ,0.00001
Control Source
Hospital 7 1,403/1,369 2.01 (1.54–2.62) 2.03 (1.74–2.36) 0.01
Population 18 9,569/11,385 1.18 (0.96–1.43) 1.30 (1.23–1.38) ,0.00001
Sample size
,500 13 1,670/1,630 1.51 (1.06–2.16) 1.61 (1.40–1.85) ,0.00001
500–1000 6 1,628/2,413 1.30 (0.91–1.86) 1.31 (1.15–1.49) ,0.00001
.1000 7 7,957/9,058 1.18 (0.91–1.53) 1.34 (1.26–1.42) ,0.00001
aSome controls in the publication by Wu (2003) et al were shared by different cancers; therefore, it was defined as four studies (head and neck cancer, bladder cancer,
lung cancer and renal cell carcinoma) in the analysis stratified by tumor type, but defined as one study in the analysis stratified by study type, ethnicity and source of
controls. In addition, the publication by Shen (2007) et al was family-based and excluded from the analysis for source of controls.
bRandom effects model.
cFixed effects model.
doi:10.1371/journal.pone.0020466.t002
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malignant transformation via fusion-bridge-breakage cycles [56].
In this meta-analysis, we found that shorter telomeres were
significantly associated with cancer risk, supporting the hypothesis
that excessive telomere shortening may play a role in accelerating
tumor onset and progression.
Although this meta-analysis showed significant associations
between shorter telomeres and overall cancer risk, some results
from stratification analysis remind us of drawing the conclusion
with caution. The stratification analysis by tumor type showed that
the association between shorter telomeres and cancer risk was
significant in bladder cancer, lung cancer, smoking-related
cancers, and cancers in the digestive system and in the urogenital
system, but not in breast cancer. Because our heterogeneity
analysis also showed that tumor type did contribute to substantial
heterogeneity, these inconsistent results by cancer types may
involve different carcinogenic mechanisms conferred by specific
telomeres in specific cancer types. Different biological pathways
(such as metabolisms of hormone, tobacco carcinogens and repair
of DNA damage) could interact with telomere length, resulting in
different efforts on cancer susceptibility. For example, several
studies found that the effect of shortened telomeres on breast
cancer risk was significant for certain subgroups, such as
premenopausal women and women with a poor antioxidative
capacity [31] but not for the overall study population [31,36]or
postmenopausal women[29]. The possible explanation may be
that the difference in hormones, particularly estrogen, may affect
telomere dynamics through its antioxidant attributes and its ability
to stimulate telomerase, which can elongate telomere ends [57]. In
addition, it has been reported that short telomeres on specific
chromosome arms may be more important for cancer risk than the
overall telomere length in a cell, and chromosome arms with the
shortest telomeres were more often found in the telomere fusions,
leading to chromosome instability [58,59]. For breast cancer,
Figure 3. Odds ratios (ORs) and 95% confidence intervals (CIs) for risk of different cancers associated with relative telomere length
(shorter vs. longer, grouped by median value of telomere length ratio). (A) Smoking-related cancers; (B) Cancers in the digestive system; (C)
Cancers in the urogenital system.
doi:10.1371/journal.pone.0020466.g003
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chromosome arms, such as gains of 1q, 8q, 17q, and 20q, and
losses of 8p, 9p, 16q, and 17p [60,61,62]. Thus, different asso-
ciations between overall telomere length and risk of different
cancers may due to the confounding effect of large number of
‘‘irrelevant’’ telomeres in the measurement.
Furthermore, the results from stratification analysis by other
factors, including study type, control source and sample size, in-
dicated that the association was more prominent in studies with
retrospective designs, hospital-based controls and smaller sample
sizes. However, these studies suffer from several major drawbacks,
such as information bias, selection bias and lower statistical power,
which may have a substantial influence on the results of studies per
se and thus on our meta-analysis as well. Specially, the difference
between studies with retrospective designs (random effects model:
OR=1.44, 95% CI=1.13–1.84; heterogeneity P,0.0001) and
prospective designs (random effects model: OR=1.21, 95%
CI=0.93–1.57; heterogeneity P,0.0001) suggests possible biases
in those studies with retrospective designs. The majority of pub-
lished studies on telomere length and cancer risk were retrospec-
tive case-control studies in which DNA samples from the cases
were collected after cancer diagnosis. This could potentially result
in reverse causation bias, where changes in surrogate tissue telo-
mere length may be a consequence of the cancer rather than a
cause. Recently, a study by Nordfja ¨llet al [63] evaluated the blood
telomere length in 959 individuals at baseline and after 10 years of
follows-up, and they found no differences in telomere length (at
baseline or at follow up) between controls and those who later
were diagnosed with cancer, which may challenge the hypothesis
that individual telomere length can predict later tumor develop-
ment. Therefore, the findings of an association between shorter
telomeres and cancer risk in this meta-analysis still require further
replication in single large prospective studies that avoid or care-
fully address potential biases.
Limitations
Some other issues in this meta-analysis also need to be addre-
ssed. Firstly, several variables may affect the length of telomeres,
such as age, sex, obesity, smoking, oxidative stress and chronic
inflammation [12,64,65,66]. However, the results of this meta-
analysis were based on unadjusted estimates, because either ORs
derived from different studies were not adjusted by the same
potential confounders or only the number of cases and controls
was provided without the detailed information of other variables.
In fact, we did try to calculate the summary ORs using adjusted
ORs available from only nine original papers [21,24,26,27,28,
29,31,36,39], and we found that there were no substantial changes
in the pooled, adjusted ORs (OR=1.41, 95% CI=1.10–1.82,
P,0.001 for heterogeneity test, I
2=82.9%). Further, there is some
evidence that treatment status (chemotherapy or radiation) can
alter telomere length [67,68], and we cannot rule out the
possibility of such an effect because of unavailable information
about the disease treatment status from the studies used in the
analysis. A more precise analysis should be conducted, if individual
data were available, allowing for the adjustment by some co-
variants and excluding those patients who had been treated.
Secondly, various methods were used to measure the relative
telomere length in those studies used in our meta-analysis,
including southern blot, Q-FISH and Q-PCR assays, which made
it difficult to directly compare or pool data from different studies.
Thirdly, the association between telomere length and cancer risk
may be affected by the types of surrogate tissues. In studies
included in this meta-analysis, DNA from multiple sources was
used, including blood, buccal cells and sputum (Table 1).
Although the majority of the inter-individual variation in telomere
length may be genetically determined [69], and cells with different
origins show a good intra-individual correlation for telomere
length in healthy subjects and case subjects [70,71], it may be
disputable for the use of hematopoietic cells to be a proxy of
average individual telomere length, because the variation in
telomere length has been observed within leukocyte subsets but
not others [72]. Therefore, consistent measurement methods and
use of the surrogate tissues are warranted in further studies on
telomere length, which may provide comparable data from
different studies.
Conclusions
Our meta-analysis provided statistical evidence for an associa-
tion between shorter telomere length and risk of human cancer,
particularly for bladder cancer, lung cancer, smoking-related
cancers, and cancers in the digestive system and in the urogenital
system. However, due to the limitations of original studies included
in the meta-analyses, larger, well-designed prospective studies are
needed to confirm these findings, which may help unravel the
underlying mechanisms of telomere shortening in cancer devel-
opment and progression.
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